MALVERN, Pa., October 26, 2023 — LifeSensors, Inc., a leading innovator in protein degradation technologies, has been invited to speak at the 6th Annual Targeted Protein Degradation Summit 2023 in…
Read More
[Malvern, PA, October 18, 2023] — LifeSensors Inc., a biotech company targeting the ubiquitin proteasome system for drug discovery and diagnostic markers, has received funding from the National Institute on...
Read More
MALVERN, Pa., SEP 21, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTAC, molecular glue drug discovery and neurodegeneration diagnostics has been invited to speak at the…
MALVERN, PA., May 30, 2023 — LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTACs, molecular glues, and neurodegeneration diagnostics will disclose direct methods to detect PROTAC & molecular glue…
By: Isabelle Wentzel Devastating Origins In the late 1950s and early 1960s, pregnant women who experienced nausea and morning sickness were prescribed thalidomide, a sedative drug meant to treat…
Hijacking the natural mechanism of the Ubiquitin Proteasome System (UPS) is emerging as a powerful medium in drug discovery through which Dr. Kadimisetty uses “TUBEs” as ubiquitin-binding entities to monitor…
Discovering Unique Ubiquitin E3 Ligase Ligands to Unlock Targeted Protein degradation Gauthami Jalagadugula, Alexandra Russell1+, Kenneth Wallace1+, Janelle Pedroza and Abdul Haseeb1 * Introduction PROteolytic TArgeting Chimeras (PROTACs) have emerged…
PROTACs and Molecular Glues: High-Throughput Quantitative Assays for Rationale Design Authors: Janelle Pedroza1, Kenneth Wallace1, Derrick Padykula, Alexandra Russell1, and Karteek Kadimisetty*1 Introduction PROTACs have emerged as new class of…